reports
Beijing Tiantan Biological Products: 1 director
A director at Beijing Tiantan Biological Products maiden bought 9,200 shares at 27.370CNY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Defensives Worthy of a Tactical Overweight As recently as last week (March 30 Int'l Compass) and throughout February/March we have recommended shifting to defensives due to our belief that $93 will cap upside on the MSCI ACWI (ACWI-US) in 2023. MSCI ACWI defensive Sectors including Health Care, Utilities, and Consumer Staples are hitting 2+ month RS highs, and are staging bullish price and RS reversals, as are precious metals miners (GDX-US). This confirms our belief that now is the time to be ...
Moody's: China's rising demand for drugs will fuel foreign pharma comp...
Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.
Moody's: China's rising demand for drugs will fuel foreign pharma comp...
Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.
- Research Department
- Jean-Jacques Le Fur
- Eric Monnier
- Jean-Jacques Le Fur
BAYER: Q4 2018 results slightly better than expected | NEUTRAL | EUR81
BAYER - NEUTRAL | EUR81(+19%) Q4 2018 results slightly better than expected A significantly better Q4 2018 than expected for Crop Science Pharmaceuticals slightly sales below consensus Consumer Health remains in the tunnel Crop Science is the focus
- MarketLine Department
Omega Pharma NV - Mergers & Acquisitions (M&A), Partnerships & Allianc...
Summary Marketline's Omega Pharma NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Omega Pharma NV since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and in...
- MarketLine Department
Antares Pharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Al...
Summary Marketline's Antares Pharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Antares Pharma, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the orga...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.